These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16565897)

  • 1. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis.
    Hayat SJ; Uppal SS; Narayanan Nampoory MR; Johny KV; Gupta R; Al-Oun M
    Clin Rheumatol; 2007 Jun; 26(6):973-5. PubMed ID: 16565897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus.
    Hayat SJ; Uppal SS
    Mod Rheumatol; 2007; 17(2):174-7. PubMed ID: 17437178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
    Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
    Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
    Aringer M; Houssiau F; Gordon C; Graninger WB; Voll RE; Rath E; Steiner G; Smolen JS
    Rheumatology (Oxford); 2009 Nov; 48(11):1451-4. PubMed ID: 19748965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: a case report.
    Principi M; Di Leo A; Ingrosso M; Pisani A; Marangi S; Amoruso A; Panella C; Francavilla A; Ierardi E
    Immunopharmacol Immunotoxicol; 2004 May; 26(2):243-8. PubMed ID: 15209360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lupus nephritis: where are we now?
    Lightstone L
    Curr Opin Rheumatol; 2010 May; 22(3):252-6. PubMed ID: 20305561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab biosimilar-induced lupus nephritis: A case report.
    Shidahara K; Katsuyama T; Hirose K; Matsumoto K; Nawachi S; Nakadoi T; Asano Y; Katayama Y; Miyawaki Y; Katsuyama E; Takano-Narazaki M; Matsumoto Y; Sada KE; Wada J
    Mod Rheumatol Case Rep; 2023 Dec; 8(1):74-76. PubMed ID: 37902434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus.
    Aringer M; Smolen JS
    Expert Opin Drug Saf; 2008 Jul; 7(4):411-9. PubMed ID: 18613805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The management of systemic lupus erythematosus with biological therapies].
    Malaise O; von Frenckell C; André B; Malaise MG
    Rev Med Suisse; 2013 Aug; 9(395):1507-11. PubMed ID: 24024419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis.
    F L; Y T; X P; L W; H W; Z S; H Z; Z H;
    Lupus; 2008 Jul; 17(7):622-9. PubMed ID: 18625634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab in a child with therapy-resistant systemic vasculitis.
    de Kort SW; van Rossum MA; ten Cate R
    Clin Rheumatol; 2006 Sep; 25(5):769-71. PubMed ID: 16267606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis.
    Sheikholeslami M; Hajialilo M; Rasi Hashemi SS; Malek Mahdavi A; Gojazadeh M; Khabbazi A
    Mod Rheumatol; 2018 May; 28(3):523-529. PubMed ID: 28753077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
    Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
    Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Role of cytokine in the pathogenesis of lupus nephritis].
    Kuroiwa T
    Nihon Rinsho; 2005 May; 63 Suppl 5():211-6. PubMed ID: 15954351
    [No Abstract]   [Full Text] [Related]  

  • 18. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey.
    De Bandt M; Sibilia J; Le Loët X; Prouzeau S; Fautrel B; Marcelli C; Boucquillard E; Siame JL; Mariette X;
    Arthritis Res Ther; 2005; 7(3):R545-51. PubMed ID: 15899041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
    Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis.
    Choi CB; Won S; Bae SC
    Lupus; 2018 May; 27(6):1007-1011. PubMed ID: 29448881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.